Etiology of schizophrenia and therapeutic options

Psychiatria Danubina

Volumn 23, Issue 3, 2011, Pages 308-315

  Rubeša, Gordana ^a   Gudelj, Lea ^a   Kubinska, Natalija ^b  

^a KBC RIJEKA   (Croatia)

^b UNIVERSITY OF RIJEKA   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE; EXCITATORY AMINO ACID; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; PHOSPHOLIPID; PROLACTIN; SEROTONIN;

CONFERENCE PAPER; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; GENETIC POLYMORPHISM; HUMAN; HUMAN GENOME PROJECT; INTERNEURON; LIMBIC SYSTEM; LIPID PEROXIDATION; NERVE CELL DIFFERENTIATION; NEUROANATOMY; NEUROPATHOLOGY; PATHOGENESIS; PROTEIN SYNTHESIS; RECEPTOR GENE; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; WORKING MEMORY;

ACETYLCHOLINE; ANTIPSYCHOTIC AGENTS; BRAIN; FATTY ACIDS, UNSATURATED; GLUTAMATES; HUMANS; SCHIZOPHRENIA; SEROTONIN;

EID: 80054096967     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (49)

1. Aghajanian GK; Marek G.J. Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Research Reviews. 2000; 31:302-12.
2. Akyol O, Herken H, Uz E, Fadilliolu E, Unal S, et al. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. Neuropsychopharm. Biol. Psychiatry, 2002; 26:995-1005.
3. Alphs LD, Summerfelt A, Lann H and Muller RJ. The negative symptom assessment: a new instrument to assess negative symptoms of schizophrenia. Psychopharmacol Bull. 1989; 25:159-163.
4. Arnold SE, Rioux L. Challenges, Status, and Opportunities for Studying Developmental Neuropathology in Adult Schizophrenia. Shizophr Bull. 2001; 27:395-416.
5. Arolt V, Rothermoundt N, Wandiger KP, Kirchern H: Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment. Mol Psychiat. 2000; 5:150-58.
6. Arvindakshan M; Ghate M, Ranjekar PK, Evans DR and Mahadik SP. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamin E and C) improves the outcome of schizophrenia. Shizophr Res. 2003; 62:195-204.
7. Baker I, Masserano j and Wyatt RJ. Serum cytokine concentrations in patients with Schizophrenia. Shizophr Res. 1996; 20:199-203.
8. Bennet S and Gronier B. Modulation of striatal dopamine release in vitro by agonists of the glycine B site of NMDA receptors; interaction with antipsychotics. Eur J Pharmacol. 2005; 527:52-9.
9. Bota RG, Sagduyu K and Munro JS. Factors associated with the prodromal progression of schizophrenia that influences the course of the illness. CNS Spectr. 2005; 10:937-42.
10. Buckley PF, Dean D, Bookstein FL, Han S, Yerukhimovich M, Min KJ et al.: A Three-Dimensional Morphometric Study of Craniofacial Shape in Schizophrenia. The American Journal of Psychiatry. 2005; 162:606-08.
11. Buretić-Tomljanović A., Giacometti J., Nadalin S., Rubeša G., Vulin m:, Tomljanović D: Phospholipid membrane abnormalities and reduced niacin skin flush response in Schizophrenia. Psych. Danubina 2008; 20:372-83.
12. Cavelier L, Jazin EE, Eriksson I, Prince J, Båve U, Oreland L et al. Decreased Cytochrome-c Oxidase Activity and Lack of Age-Related Accumulation of Mitochondrial DNA Deletions in the Brains of Schizophrenics. Genomics. 1995; 29:217-24.
13. Clinton SM, Ibrahim HM, Frey KA, Davis KL, Haroutunian V and Meador-Woodruff JH. Dopaminergic abnormalities in select thalamic nuclei in schizophrenia: involvement of the intracellular signal integrating proteins calcyon and spinophilin. Am J Psychiatry 2005; 162:1859-71.
14. Coyle JT. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 2006; 26:365-84.
15. Cziko G. Universal selection theory and the second Darwinian revolution. Cambridge: MIT Press (A Bradford Book). 1995.
16. Davatzikos C, Shen D, Gur RC, Wu X, Liu D, Fan Y et al. Whole-Brain Morphometric Study of Schizophrenia Revealing a Spatially Complex Set of Focal Abnormalities. Arch Gen Psychiatry. 2005; 62:1218-27.
17. DeLisi LE. Defining the course of brain structural change and plasticity in schizophrenia. Psychiatry Res. 1999; 92:1-9.
18. Faroogui AA, Horrocks LA, Faroogui T. Deacylation and reacylation of neural membrane glycerophospholipids. J Mol Neurosci. 2000; 14:123-35.
19. Feldberg W. Possible association of schizophrenia with a disturbance in prostaglandin metabolism: a physiological hypothesis. Psychiatr Med 1976; 6:359-369.
20. Freeman MP, Hibbeln JR, Wisner KL, Davis JM, Mischoulon D et al.Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. Journal of Clinical Psychiatry, 2006, 67:1954-67.
21. Gharaibeh WS, Rohlf FJ, Slice DE and DeLisi LE. A geometric morphometric assessment of change in midline brain structural shape following a first Episode of schizophrenia. Biological Psychiatry. 2000; 48:398-405.
22. Herken H, Uz E, Özyurt H, Sögüt S, Virit O and Akyol Ö Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Molecular psychiatry, 2001; 6:66-73.
23. Horrobin DF, Manku MS, Morse-Fisher N, Vaddadi KS, Courtney P, et al. Essential fatty acids in plasma phospholipids in schizophrenics. Biological psychiatry. 989; 25:562-68.
24. Ilan T, Ben-Shachar D, Strous RD, Mazor M, Sheinkman A, Kotler M et al. A peripheral marker for schizophrenia: Increased levels of D3 dopamine receptor mRNA in blood lymphocytes. PNAS. 2001; 98:625-28.
25. Javitt DC. Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients. Curr Opin Psychiatri. 2006; 19:151-7.
26. Johnson MR, Morris NA, Astur RS, Calhoun VD, Mathalon DH, Kiehl KA and Pearlson GD. A functional magnetic resonance imaging study of working memory abnormalities in schizophrenia. Biol Psychiatry. 2006; 60:11-21.
27. Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B et al. Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology. 2006; 31:1991-2001.
28. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC et al. Initial sequencing and analysis of the human genome. Nature 2001; 409:860-921.
29. McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C and Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med. 2003; 139:802-09.
30. Moises HW, Zoega T and Gottesman II. Human Genome data analyzed by an evolutionary method suggests a decrease in cerebral protein-synthesis rate as cause of schizophrenia and an increase as antipsychotic mechanism. BMC Psychiatry 2002; 2:8.
31. Muck-Šeler D, Pivac N, Mustapić M, Deželjin M, Šagud M, Mihaljević-Peleš A et al.: Trombocitni serotonin: periferni biokemijski pokazatelj u etiologiji i liječenju shizofrenije. Drugi hrvatski kongres o psihofarmakoterapiji s meCrossed d signunarodnim sudjelovanjem: zbornik sažetaka - Zagreb: Medicinska naklada. 2005; 39-41.
32. Nadalin. S, Rubeša G., Giacometti J., Vulin M., Tomljanović D., Vraneković J., et al.: Ban I polymorphism of cytosolic phospholipase A2 gene is associated with age at onset in male patients with schizophrenia and schizoaffective disorder. Prostaglandins Leukotrienes Essent Fatty Acids 2008; 78:351-60.
33. Natesan S. Reckless GE, Nobrega JN, Fletcher PJ and Kapur S. Diassociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology. 2006; 3:1854-63.
34. Ngan ETC, Yatham LN, Ruth TJ and Liddle PF. Decreased Serotonin 2A Receptor Densities in Neuroleptic-Naive Patients With Schizophrenia: A PET Study Using [18F Setoperone. The American Journal of Psychiatry. 2000; 57:1016-18.
35. Peet M and Horrobin DF: A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J of Psychiatric Research. 2002; 36:7-18.
36. Prolong E, Magistretti P and Stoop R. Cellular perspectives on the glutamate-monoamine interactions in limbic lobe structures and their relevance for some psychiatric disorders. Prog Neurobiol. 2002; 67:173-202.
37. Puri BK, Richardson AJ, Horrobin DF, Easton TSaeed N, Oatridge A. Et al. Eicosapentaenoic acid treatment in schizophrenia associated with symptom remission, normalization of blood fatty acids, reduced neuronal membrane phospholipid turnover, and structural brain changes. International Journal of Clinical Practice, 2000; 54:57-63.
38. Remington G, Mamo D, Labelle A, Reiss J, Shammi C, Mannaert E et al. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry. 2006; 163:396-401.
39. Reynolds GP, Yao Z, Zhang XB, Sun J and Zhang ZJ: Pharmacogenics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphism separately associate with positive and negative symptom response. Eur Neuropsychopharmacol 2004; 15:143-51.
40. Richardson AJ, Easton T et Puri BK. Red cell and plasma fatty acid changes accompanying symptom remission in patients with schizophrenia treated with eicosapentaenoic acid. European Neuropsychopharmacology. 2000; 10:189-193.
41. Richardson AJ. Omega-3 fatty acids in ADHD and related neurodevelopmental disorders. Int Rev Psychiatry. 2006, 18:155-72.
42. Ross BM, Hudson C, Erlich J, Warsh JJ, Kish SJ. Increased phospholipid breakdown in schizophrenia. Evidence for the involvement of a calcium-independent phospholipase A2. Arch Gen Psychiatry. 1997; 54:487-94.
43. Sampath H and Ntambi JM. Polyunsaturated fatty acid regulation of lipid metabolism. Annu Rev Nutr. 2005; 25:317-40.
44. Scarr E, Beneyto M, Meador-Woodruff JH and Dean B: Cortical glutamatergic markers in schizophrenia. Neuropsychopharmacology. 2005; 30:1521-31.
45. Selemon LD. Regionally diverse cortical pathology in schizophrenia: clues to the aetiology of the disease. Schizophr Bull. 2001; 27:349-77.
46. Skosnik PD and Yao JK. From membrane phospholipid defects to altered neurotransmission is arrachidonal - the pathophysiology of schizophrenia? Prostagl Leukot Essent Fatty Acids. 2003; 69:367-84.
47. Takahashi H, Higuchi M and Suhara T. The role of extrastriatal dopamine D2 receptors in schizophrenia. Biol Psychiatry. 2006; 59:919-28.
48. Thomas J, Raedler MD,. Knable MB, Jones DW., Urbina RA, G. Gorey JG, ET AL. In Vivo Determination of Muscarinic Acetylcholine Receptor Availability in Schizophrenia. The American Journal of Psychiatry. 2003; 60:118-27.
49. Yao JK and van Kammen DP. Membrane Phospholipids and Cytokine Interaction in Schizophrenia Int Rev Neurobiol 2004; 59:297-26.